Biopharmaceutical CMO Market Rising in United States | Fortune Business Insights
The global biopharmaceutical CMO market size reached USD 9.64 billion in 2020. The market valuation is slated to rise from USD 11.56 billion in 2021 to USD 26.49 billion in 2028 at a CAGR of 12.6% during the forecast duration. The market expansion will be influenced by the increasing number of novel drug development projects entering clinical pipelines. As per data published by Contract Pharma in 2019, overall drug development capacity is set to increase by more than 60% as more and more CMOs invest to help meet the future demand. Fortune Business Insights presents this information in its report titled “Biopharmaceutical CMO Market, 2021-2028.”
A
biopharmaceutical Contract Manufacturing Organization (CMO) is a firm that
serves other companies in the biopharmaceutical sector on a contract basis.
CMOs offer a wide portfolio of services ranging from manufacturing to
packaging. Relying on such organizations allows biopharmaceutical companies to
outsource their production operations, allowing them to emphasize more on drug
discovery, development, and marketing. Many small biotechnology and
biopharmaceutical companies outsource their fill and finish manufacturing needs
as they lack the required in-house production capacity. Outsourcing also
enables them to reduce the need for capital expenditures.
Get Sample PDF Brochure:
https://www.fortunebusinessinsights.com/enquiry/sample/biopharmaceutical-cmo-market-103346
|
North America |
United States, Canada and Mexico |
|
Europe |
Germany, UK, France, Italy, Russia and Turkey
etc. |
|
Asia-Pacific |
China, Japan, Korea, India, Australia, Indonesia,
Thailand, Philippines, Malaysia and Vietnam etc. |
|
South America |
Brazil, Argentina, Columbia etc. |
|
Middle East & Africa |
Saudi Arabia, UAE, Egypt, Nigeria and South
Africa |
Notable Industry Developments:
June 2021 – Danaher completed the
acquisition of Aldevron, a biotech contract manufacturing and development
organziation.
April 2021 – Thermo Fisher Scientific acquired PPD, Inc., one of the world’s leading
providers of clinical research and pharmaceutical manufacturing services.
COVID-19 Impact:
Emerging Opportunities amid Accelerated
COVID-19 Vaccine Development Efforts
Contract manufacturing services have experienced positive demand during the pandemic owing to increased allocation of biopharmaceutical contracts to CMOs between 2019 and 2020. The pandemic saw major biopharmaceutical companies accelerate the development of safe and effective COVID-19 vaccines as well as new therapies for the treatment of those infected. As of September 2021, there are over 1,000 vaccine development efforts in progress for COVID-19, the Global Data Pharma Intelligence Center reports. Also, more than 230 contract manufacturing agreements for COVID-19 vaccine development have been disclosed publicly. The aforementioned factors have augmented the biopharmaceutical CMO market growth during the pandemic.
Report Coverage
The report offers:
·
Major growth drivers, restraining
factors, opportunities, and potential challenges for the market.
·
Comprehensive insights into the
regional developments.
·
List of major industry players.
·
Key strategies adopted by the market
players.
·
Latest industry developments such as
product launches, partnerships, mergers, and acquisitions.
Speak
To Our Analyst:
https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/biopharmaceutical-cmo-market-103346
About Us:
Fortune Business Insights™ delivers accurate data and innovative
corporate analysis, helping organizations of all sizes make appropriate
decisions. We tailor novel solutions for our clients, assisting them to address
various challenges distinct to their businesses. Our aim is to empower them
with holistic market intelligence, providing a granular overview of the market
they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Comments
Post a Comment